Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von NightTrain 

Novo Nordisk A/S ADR diskutieren

Novo Nordisk A/S ADR

WKN: 866931 / Symbol: NVO / Name: Novo Nordisk / Aktie / Pharmazeutika / Large Cap /

118,50 €
2,16 %

Buy Novo Nordisk A/S ADR

Sell Novo Nordisk A/S ADR

Buy Novo Nordisk A/S ADR

Einschätzung Buy
Rendite (%) -16,96 %
Kursziel 28,58
Veränderung
Endet am 29.03.24

Novo Nordisk A/S (NYSE: NVO) had its price target raised by analysts at BTIG Research from $20.00 to $31.00. They now have a "buy" rating on the stock.
Ratings data for NVO provided by MarketBeat

Einschätzung Buy
Rendite (%) 39,15 %
Kursziel 104,76
Veränderung
Endet am 02.10.24

Novo Nordisk A/S (NYSE: NVO) is now covered by analysts at Argus. They set a "buy" rating and a $110.00 price target on the stock.
Ratings data for NVO provided by MarketBeat

Einschätzung Buy
Rendite (%) 27,80 %
Kursziel 110,39
Veränderung
Endet am 01.12.24

Novo Nordisk A/S (NYSE: NVO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $120.00 price target on the stock.
Ratings data for NVO provided by MarketBeat

Einschätzung Buy
Rendite (%) 28,08 %
Kursziel 106,28
Veränderung
Endet am 04.12.24

Novo Nordisk A/S (NYSE: NVO) had its price target raised by analysts at TD Cowen from $105.00 to $115.00. They now have an "outperform" rating on the stock.
Ratings data for NVO provided by MarketBeat

Novo Nordisk A/S (NYSE: NVO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for NVO provided by MarketBeat

Einschätzung Buy
Rendite (%) 24,86 %
Kursziel 110,32
Veränderung
Endet am 23.01.25

Novo Nordisk A/S (NYSE: NVO) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $120.00 price target on the stock.
Ratings data for NVO provided by MarketBeat

Einschätzung Buy
Rendite (%) 11,84 %
Kursziel 128,80
Veränderung
Endet am 01.02.25

Novo Nordisk A/S (NYSE: NVO) had its price target raised by analysts at Cantor Fitzgerald from $120.00 to $140.00. They now have an "overweight" rating on the stock.
Ratings data for NVO provided by MarketBeat

Einschätzung Buy
Rendite (%) 4,49 %
Kursziel 130,44
Veränderung
Endet am 14.02.25

Novo Nordisk A/S (NYSE: NVO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $140.00 price target on the stock.
Ratings data for NVO provided by MarketBeat

Einschätzung Buy
Rendite (%) 5,88 %
Kursziel 129,46
Veränderung
Endet am 20.02.25

Novo Nordisk A/S (NYSE: NVO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $140.00 price target on the stock.
Ratings data for NVO provided by MarketBeat

Einschätzung Buy
Rendite (%) -1,56 %
Kursziel 147,49
Veränderung
Endet am 20.03.25

Novo Nordisk A/S (NYSE: NVO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $160.00 price target on the stock.
Ratings data for NVO provided by MarketBeat

Einschätzung Buy
Rendite (%) -1,25 %
Kursziel 148,38
Veränderung
Endet am 01.04.25

Novo Nordisk A/S (NYSE: NVO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $160.00 price target on the stock.
Ratings data for NVO provided by MarketBeat

Einschätzung Buy
Rendite (%) -0,84 %
Kursziel 153,17
Veränderung
Endet am 12.04.25

Novo Nordisk A/S (NYSE: NVO) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $163.00 price target on the stock.
Ratings data for NVO provided by MarketBeat